Yaws

AB1_YAWNS

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — A66 Cause of death: ICD-10 — A66 2 out of 7 registries used, show all original rules.	51
4. Check minimum number of events None	51
5. Include endpoints None	51
6. Filter based on genotype QC (FinnGen only)	48

Control definitions (FinnGen only)

Control exclude: AB1_OTHER_SPIROCHAETAL

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF5

NAME	AB1_YAWNS
CONTROL_EXCLUDE	AB1_OTHER_SPIROCHAETAL
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	A66
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	A66
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Yaws based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	432	212	219
Only index persons	412	200	212
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	33.17	36.75	29.72
Only index persons	33.39	36.30	30.65

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	48	25	23
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	53.52	45.06	62.72

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
51: Matched controls
510

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

A66.1

ICD-10 Finland

Multiple papillomata and wet crab yaws

+∞

21.3

A66.0

ICD-10 Finland

Initial lesions of yaws

+∞

9.7

A66.2

ICD-10 Finland

Other early skin lesions of yaws

+∞

7.5

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Pharmacy visit
OMOP4822462 [581458]

—

5.9e-01

1.1e+00

2.1e+00

2.6e-01

—

cases:88.00%

controls:80.24%

cases:62.00%

controls:35.89%

cases:16.00%

controls:2.22%

cases:44.00%

controls:37.78%

—

398

178

318

485

187

308

—

General Surgery
2 [38004447]

—

1.3e+00

—

1.0e+50

2.8e+00

—

cases:16.00%

controls:4.84%

—

cases:20.00%

controls:0.00%

cases:14.00%

controls:1.01%

—

472

—

496

490

—

Case Management Agency
251B00000X [38004193]

—

4.7e-01

8.8e-01

2.7e+00

7.3e-01

—

cases:50.00%

controls:38.51%

cases:32.00%

controls:16.33%

cases:20.00%

controls:1.61%

cases:30.00%

controls:17.17%

—

191

305

415

488

410

—

Outpatient Visit
OP [9202]

—

7.4e-01

1.0e+00

1.0e+50

1.6e+00

—

cases:60.00%

controls:41.73%

cases:24.00%

controls:10.28%

cases:62.00%

controls:0.00%

cases:36.00%

controls:10.51%

—

207

289

445

496

443

—

Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

digoxin; oral, parenteral
C01AA05 [21600234]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Intraoral radiographic dental examination
EB1AA [2001301903]

—

1.2e+00

—

cases:12.00%

controls:4.03%

—

476

—

pravastatin; oral
C10AA03 [21601858]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

desloratadine; oral
R06AX27 [21603526]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Differential panel, method unspecified - Blood
69738-3 [42870588]

—

-1.0e+50

—

cases:0.00%

controls:2.62%

—

483

—

fluconazole; oral, parenteral
J02AC01 [21603080]

—

-1.0e+50

—

cases:0.00%

controls:2.82%

—

482

—

Limited function/disability (L)
L28 [2002000647]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]

—

3.1e-01

—

-1.0e+50

—

cases:14.00%

controls:10.69%

—

cases:0.00%

controls:1.41%

—

443

—

488

—

hypromellose
S01KA02 [21605115]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

insulin lispro; parenteral
A10AC04 [21600726]

—

-1.0e+50

—

cases:0.00%

controls:3.23%

—

480

—

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

—

4.2e-01

—

-1.0e+50

—

cases:14.00%

controls:9.68%

—

cases:0.00%

controls:1.82%

—

448

—

486

—

Prothrombin time (PT) actual/Normal
5894-1 [3033658]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

ispaghula (psylla seeds); oral
A06AC01 [21600555]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

leuprorelin; implant, parenteral
L02AE02 [21603825]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

levothyroxine sodium; oral, parenteral
H03AA01 [21602754]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Dyspnoea
R06.0 [45558449]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Type 1 diabetes mellitus, Without complications
E10.9 [45581351]

—

-1.0e+50

—

cases:0.00%

controls:3.23%

—

480

—

pantoprazole; oral, parenteral
A02BC02 [21600097]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

485

—

tamsulosin and dutasteride
G04CA52 [21602673]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]

—

4.2e-01

-1.0e+50

—

cases:14.00%

controls:9.68%

cases:0.00%

controls:1.21%

—

448

490

—

Outcome of delivery
Z37 [45581024]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]

—

-1.0e+50

—

cases:0.00%

controls:1.82%

—

486

—

Health maint/preventive medicine
A98 [2002000231]

—

-9.6e-03

—

cases:16.00%

controls:16.13%

—

416

—

Osmolality of Urine
2695-5 [3026782]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

Basophils [#/volume] in Blood
26444-0 [3006315]

—

-1.0e+50

—

cases:0.00%

controls:4.44%

—

474

—

valaciclovir; oral
J05AB11 [21603137]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Medical doctor
Z2221 [2001311556]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

pivmecillinam; oral
J01CA08 [21602827]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

Home Visit
OMOP4822459 [581476]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

cases:0.00%

controls:1.01%

—

488

—

490

—

Hand Surgery
40 [38004480]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

allopurinol; oral, parenteral
M04AA01 [21604131]

—

-1.0e+50

—

cases:0.00%

controls:2.62%

cases:0.00%

controls:1.01%

—

483

491

—

carbamazepine; oral, rectal
N03AF01 [21604417]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Other early skin lesions of yaws
A66.2 [45576245]

—

1.0e+50

—

cases:14.00%

controls:0.00%

—

496

—

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

—

-1.0e+50

—

cases:0.00%

controls:4.23%

—

475

—

FEV1 percent change
69983-5 [42868472]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

cefalexin; oral
J01DB01 [21602870]

—

4.6e-01

—

cases:14.00%

controls:9.27%

—

450

—

Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Spontaneous vertex delivery
O80.0 [45577661]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

—

1.2e-01

9.2e-01

—

cases:22.00%

controls:19.96%

cases:10.00%

controls:4.23%

—

397

475

—

Monocytes [#/volume] in Blood
26484-6 [3001604]

—

-1.0e+50

—

cases:0.00%

controls:4.44%

—

474

—

telmisartan; oral
C09CA07 [21601830]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

FEV1 --post bronchodilation
20155-8 [3023550]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Pediatric Medicine
37 [38004477]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Urinary tract infection, site not specified
N39.0 [45548665]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

losartan and diuretics
C09DA01 [21601834]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Urgent procedure
ZXD05 [2001311386]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Psychiatry
26 [38004469]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

cases:0.00%

controls:1.01%

—

491

—

490

—

ibuprofen
R02AX02 [1588667]

—

2.9e-01

—

cases:14.00%

controls:10.89%

—

442

—

FEV1
20150-9 [3024653]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]

—

-1.0e+50

—

cases:0.00%

controls:2.22%

—

485

—

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

—

2.2e-01

—

cases:18.00%

controls:14.92%

—

422

—

calcium (different salts in combination); oral
A12AA20 [21600872]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Urology
34 [38004474]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

—

3.6e-01

—

cases:18.00%

controls:13.31%

—

430

—

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

—

-1.0e+50

—

cases:0.00%

controls:4.03%

—

476

—

montelukast; oral
R03DC03 [21603356]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

metformin; oral
A10BA02 [21600747]

—

-1.0e+50

—

cases:0.00%

controls:1.82%

—

486

—

insulin lispro; parenteral
A10AD04 [21600732]

—

-1.0e+50

—

cases:0.00%

controls:3.23%

—

480

—

Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

paracetamol; oral, parenteral, rectal
N02BE01 [21604344]

—

9.1e-01

1.7e+00

—

cases:28.00%

controls:13.51%

cases:10.00%

controls:2.02%

—

429

486

—

Multiple papillomata and wet crab yaws
A66.1 [45556914]

—

1.0e+50

—

cases:38.00%

controls:0.00%

—

496

—

atorvastatin; oral
C10AA05 [21601860]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

—

-1.2e-01

—

-1.0e+50

—

cases:12.00%

controls:13.31%

—

cases:0.00%

controls:2.63%

—

430

—

482

—

Outpatient Hospital
22 [8756]

—

6.5e-01

—

cases:12.00%

controls:6.65%

—

463

—

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

—

2.4e-01

—

cases:18.00%

controls:14.72%

—

423

—

Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]

—

3.4e-01

—

-1.0e+50

—

cases:12.00%

controls:8.87%

—

cases:0.00%

controls:1.01%

—

452

—

490

—

Telehealth
OMOP5556618 [722455]

—

1.5e+00

—

cases:18.00%

controls:4.64%

—

473

—

perindopril; oral
C09AA04 [21601788]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Open wound of scalp
S01.0 [45592468]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

FVC percent change Respiratory system
69982-7 [42868471]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Initial lesions of yaws
A66.0 [45605212]

—

1.0e+50

—

cases:16.00%

controls:0.00%

—

496

—

Malignant neoplasm of prostate
C61 [45547509]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]

—

8.3e-02

—

cases:10.00%

controls:9.27%

—

450

—

General anesthesia, balanced
WX408 [2001310808]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Sensorineural hearing loss, bilateral
H90.3 [45576850]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

naproxcinod
M01AE18 [40254094]

—

-1.0e+50

—

cases:0.00%

controls:2.42%

—

484

—

Other blockage of nerve
WX290 [2001310792]

—

-1.0e+50

—

cases:0.00%

controls:2.42%

—

484

—

Platelets [#/volume] in Blood
26515-7 [3007461]

—

1.6e-01

9.2e-01

—

cases:22.00%

controls:19.35%

cases:10.00%

controls:4.23%

—

400

475

—

Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]

—

-1.0e+50

—

cases:0.00%

controls:2.62%

—

483

—

naproxen; oral, rectal
M01AE02 [21603968]

—

-1.0e+50

—

cases:0.00%

controls:2.42%

—

484

—

amlodipine; oral
C08CA01 [21601747]

—

6.8e-01

—

-1.0e+50

—

cases:12.00%

controls:6.45%

—

cases:0.00%

controls:1.62%

—

464

—

487

—

Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Monocytes/Leukocytes in Blood
26485-3 [3019069]

—

-1.0e+50

—

cases:0.00%

controls:4.03%

—

476

—

Emergency Room Visit
ER [9203]

—

3.9e-01

—

1.0e+50

-1.0e+50

—

cases:14.00%

controls:9.88%

—

cases:12.00%

controls:0.00%

cases:0.00%

controls:1.62%

—

447

—

496

487

—

Simple examination of mouth
SAA01 [2001310274]

—

8.6e-01

—

-1.0e+50

—

cases:16.00%

controls:7.46%

—

cases:0.00%

controls:1.41%

—

459

—

488

—

Basophils/Leukocytes in Blood
30180-4 [3022096]

—

-1.0e+50

—

cases:0.00%

controls:4.03%

—

476

—

IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Sleep apnoea
G47.3 [45562094]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

—

1.1e-01

9.2e-01

—

cases:22.00%

controls:20.16%

cases:10.00%

controls:4.23%

—

100

396

475

—

budesonide; inhalant
R03BA02 [21603285]

—

-1.0e+50

—

cases:0.00%

controls:3.83%

—

477

—

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

—

-1.0e+50

—

cases:0.00%

controls:4.44%

—

474

—

Emergency Room and Inpatient Visit
ERIP [262]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]

—

5.2e-01

—

-1.0e+50

—

cases:18.00%

controls:11.49%

—

cases:0.00%

controls:1.41%

—

439

—

488

—

No procedures
SPAT1301 [2001700402]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

latanoprost
S01EE01 [21603710]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

metoprolol and felodipine
C07FB02 [21601742]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

candesartan and diuretics
C09DA06 [21601838]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Leukocytes [#/volume] in Blood
26464-8 [3010813]

—

1.2e-01

9.2e-01

—

cases:22.00%

controls:19.96%

cases:10.00%

controls:4.23%

—

397

475

—

Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Neurology
13 [38004458]

—

8.7e-01

—

cases:10.00%

controls:4.44%

—

474

—

Otolaryngology
4 [38004449]

—

1.4e+00

—

1.0e+50

—

cases:12.00%

controls:3.23%

—

cases:28.00%

controls:0.00%

—

480

—

496

—

furosemide; oral, parenteral
C03CA01 [21601518]

—

-1.0e+50

—

cases:0.00%

controls:1.82%

—

486

—

acetylsalicylic acid; oral
B01AC06 [21600991]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Essential (primary) hypertension
I10 [45591453]

—

7.8e-01

—

-1.0e+50

—

cases:10.00%

controls:4.84%

—

cases:0.00%

controls:1.41%

—

472

—

488

—

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

—

-1.0e+50

—

cases:0.00%

controls:4.84%

—

472

—

hydroxocobalamin; parenteral
B03BA03 [21601123]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Inpatient Hospital
21 [8717]

—

4.6e-01

—

cases:16.00%

controls:10.69%

—

443

—

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

—

1.2e-01

9.2e-01

—

cases:22.00%

controls:19.96%

cases:10.00%

controls:4.23%

—

397

475

—

Hyperkeratosis of yaws
A66.3 [45566518]

—

1.0e+50

—

cases:10.00%

controls:0.00%

—

496

—

ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Atrial fibrillation and flutter
I48 [45596206]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

486

—

isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

486

—

bisoprolol; oral
C07AB07 [21601689]

—

1.1e-01

—

cases:12.00%

controls:10.89%

—

442

—

Calprotectin [Mass/mass] in Stool
38445-3 [3048689]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

esomeprazole; oral, parenteral
A02BC05 [21600100]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Periodontal treatment
SDA03 [2001310328]

—

-1.0e+50

—

cases:0.00%

controls:2.42%

—

484

—

Right side
ZXA00 [2001311346]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Rheumatology
66 [38004491]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Other specified counselling
Z71.8 [45581061]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Thorax X-ray examination
GD1AA [2001303617]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Eosinophils [#/volume] in Blood
26449-9 [3013115]

—

-1.0e+50

—

cases:0.00%

controls:4.44%

—

474

—

Abdominal ultrasound examination
JN3AE [2001305555]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Low back pain
M54.5 [45553207]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

FEV1/FVC
19926-5 [3011505]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

—

1.2e-01

9.2e-01

—

cases:22.00%

controls:19.96%

cases:10.00%

controls:4.23%

—

397

475

—

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

—

3.5e-01

1.1e+00

—

cases:22.00%

controls:16.53%

cases:10.00%

controls:3.43%

—

414

479

—

escitalopram; oral
N06AB10 [21604718]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

—

5.0e-01

1.5e+00

—

cases:18.00%

controls:11.69%

cases:10.00%

controls:2.42%

—

438

484

—

covid-19, RNA-based vaccine
J07BN01 [954934]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

486

—

insulin (human); parenteral
A10AB01 [21600715]

—

-1.0e+50

—

cases:0.00%

controls:3.02%

—

481

—

Complicated extraction of tooth
EBA05 [2001301924]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

alprazolam; oral
N05BA12 [21604577]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]

—

4.4e-01

—

-1.0e+50

—

cases:16.00%

controls:10.89%

—

cases:0.00%

controls:1.41%

—

442

—

488

—

ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]

—

2.9e-01

—

cases:14.00%

controls:10.89%

—

442

—

terbutaline; inhalant
R03AC03 [21603257]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

acrivastine; oral
R06AX18 [21603518]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

486

—

citalopram; oral, parenteral
N06AB04 [21604712]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

hydroxocobalamin
V03AB33 [21605256]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

zolpidem; oral
N05CF02 [21604655]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]

—

1.2e+00

—

cases:10.00%

controls:3.23%

—

480

—

oxazepam; oral
N05BA04 [21604569]

—

-1.0e+50

—

cases:0.00%

controls:2.22%

—

485

—

ramipril; oral
C09AA05 [21601789]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

cases:0.00%

controls:1.62%

—

490

—

487

—

Inpatient Visit
IP [9201]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

enalapril; oral, parenteral
C09AA02 [21601786]

—

1.4e+00

—

-1.0e+50

—

cases:10.00%

controls:2.62%

—

cases:0.00%

controls:1.41%

—

483

—

488

—

Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

norfloxacin; oral
J01MA06 [21603013]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

etoricoxib; oral
M01AH05 [21603996]

—

6.6e-01

—

-1.0e+50

—

cases:10.00%

controls:5.44%

—

cases:0.00%

controls:1.41%

—

469

—

488

—

Medical Oncology
90 [38004507]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Infiltration anesthesia
WX110 [2001310767]

—

7.0e-01

—

-1.0e+50

—

cases:10.00%

controls:5.24%

—

cases:0.00%

controls:1.41%

—

470

—

488

—

losartan; oral
C09CA01 [21601824]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Audiology
64 [38004489]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

insulin lispro; parenteral
A10AB04 [21600718]

—

-1.0e+50

—

cases:0.00%

controls:3.23%

—

480

—

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

—

-1.0e+50

—

cases:0.00%

controls:2.02%

—

486

—

CBC panel - Blood by Automated count
58410-2 [40761511]

—

-1.4e-01

—

cases:12.00%

controls:13.51%

—

429

—

pH of Serum or Plasma
2753-2 [3018418]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Telephone prescription or other care instructions
WZB00 [2001310884]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]

—

2.2e-01

—

cases:12.00%

controls:9.88%

—

447

—

Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]

—

5.4e-01

—

cases:10.00%

controls:6.05%

—

466

—

Pulmonary Disease
29 [38004472]

—

-1.0e+50

—

cases:0.00%

controls:3.02%

—

481

—

MCH [Entitic mass]
28539-5 [3035941]

—

1.2e-01

9.2e-01

—

cases:22.00%

controls:19.96%

cases:10.00%

controls:4.23%

—

397

475

—

Teaching
WZC30 [2001310891]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Epithelial cells [#/volume] in Urine
30383-4 [3000850]

—

-1.0e+50

—

cases:0.00%

controls:1.81%

—

487

—

terbinafine; oral
D01BA02 [21601967]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

gabapentin; oral
N02BF01 [955005]

—

-1.0e+50

—

cases:0.00%

controls:1.61%

—

488

—

Laboratory Visit
OMOP4822461 [32036]

—

2.2e-01

1.3e+00

—

cases:28.00%

controls:23.79%

cases:20.00%

controls:6.25%

—

118

378

465

—

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

—

-1.0e+50

—

cases:0.00%

controls:1.41%

—

489

—

Orthopedic Surgery
20 [38004465]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

490

—

Obstetrics / Gynecology
16 [38004461]

—

-1.0e+50

1.0e+50

—

cases:0.00%

controls:1.41%

cases:12.00%

controls:0.00%

—

489

496

—

Normoblasts [#/volume] in Blood
715-3 [3021589]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:6.45%

cases:0.00%

controls:1.81%

—

cases:0.00%

controls:1.01%

—

464

487

—

490

—

Internal Medicine
11 [38004456]

—

1.2e+00

—

cases:24.00%

controls:8.47%

—

454

—

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

FEV1/FVC --post bronchodilation
69970-2 [42868459]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

levocetirizine; oral
R06AE09 [21603498]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

491

—

Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]

—

-1.0e+50

—

cases:0.00%

controls:2.22%

—

485

—

enoxaparin; parenteral
B01AB05 [21600976]

—

-1.0e+50

—

cases:0.00%

controls:1.21%

—

490

—

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

—

2.4e-01

—

-1.0e+50

—

cases:10.00%

controls:8.06%

—

cases:0.00%

controls:1.62%

—

456

—

487

—

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

—

-3.9e-01

—

-1.0e+50

—

cases:10.00%

controls:14.11%

—

cases:0.00%

controls:2.83%

—

426

—

481

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

169

3.70

4.82

2.5

1.9

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

7.37

2.95

1.3

1.7

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

6.62

2.78

1.5

2.3

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.69

2.63

2.9

2.5

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

303

2.80

2.27

3.1

3.2

—

(4035726) Immunohistochemistry procedure

3.11

2.22

1.4

1.5

—

(3031040) Bacteria [#/volume] in Urine by Automated count

273

2.54

2.19

3.6

3.8

—

33.80

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.59

2.12

2.1

1.8

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

4.91

1.99

2.4

2.6

333.80

421.11

ug/l

—

(3026008) Bacteria identified in Urine by Culture

102

2.18

1.74

3.7

2.6

—

(3000494) Fungus identified in Specimen by Culture

2.64

1.71

1.3

1.4

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

2.40

1.45

3.2

7.5

104.60

104.19

mmol/l

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

155

1.88

1.34

3.2

1.9

94.32

94.42

pmol/l

0.00

(3022948) Iron [Moles/volume] in Serum or Plasma

2.03

1.17

2.0

2.4

10.50

15.84

umol/l

1.27

(3042936) Bacteria identified in Isolate by Culture

2.06

1.13

1.8

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

2.53

1.11

1.4

1.3

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.01

1.05

16.9

4.5

13.54

9.29

umol/l

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.16

1.04

1.1

1.7

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.97

1.03

2.3

1.5

—

(3032080) INR in Blood by Coagulation assay

188

1.65

0.92

21.0

11.8

1.37

1.20

inr

0.62

153

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.88

0.82

2.3

1.7

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

1.64

0.69

3.5

2.0

0.73

0.97

mg/l

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

179

1.52

0.69

4.4

2.9

—

estimate

—

(3044640) Blood type and Crossmatch panel - Blood

125

1.54

0.65

3.1

2.7

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

230

1.48

0.63

13.5

7.1

14.35

11.66

umol/l

0.26

218

(40758558) Short blood count panel - Blood

135

1.52

0.63

9.4

6.9

—

(3023368) Bacteria identified in Blood by Culture

108

1.55

0.62

4.9

4.3

—

(3037551) Cancer Ag 125 [Units/volume] in Serum or Plasma

0.00

0.61

0.0

2.5

—

18.29

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.55

0.58

1.6

2.2

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.65

0.56

1.8

1.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.56

0.55

3.0

3.5

—

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

1.59

0.51

1.8

2.3

2.40

2.46

mmol/l

—

(3027945) Reticulocytes/Erythrocytes in Blood

1.57

0.50

4.9

2.8

2.17

1.82

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

1.50

0.48

12.9

5.3

278.29

235.94

u/l

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.46

0.47

3.0

1.7

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

1.50

0.45

2.5

1.7

338.00

442.76

pmol/l

1.27

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.39

0.43

1.6

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.42

0.0

1.4

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

0.00

0.42

0.0

1.1

—

(3041096) Erythrocytes [Presence] in Urine by Automated

132

0.70

0.38

2.3

3.0

—

0.00

estimate

—

(3003396) Base excess in Arterial blood by calculation

1.52

0.38

3.2

6.9

1.38

0.76

mmol/l

—

(1761868) Lipid panel - Serum or Plasma

184

0.74

0.37

3.6

3.3

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.39

0.33

1.7

—

(3019309) Folate [Moles/volume] in Red Blood Cells

1.43

0.33

1.6

1.7

1863.70

1208.84

nmol/l

—

(3022145) Colonoscopy Study observation

1.37

0.32

1.1

1.3

—

(3003694) ABO and Rh group [Type] in Blood

122

1.33

0.31

1.8

1.5

—

(40761511) CBC panel - Blood by Automated count

448

0.74

0.30

13.8

13.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.32

0.30

1.5

1.7

—

(40768797) Stomach Pathology biopsy report

1.30

0.29

1.4

1.3

—

(3026493) Urate [Moles/volume] in Serum or Plasma

107

1.29

0.25

4.8

3.1

357.00

334.90

umol/l

0.31

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.39

0.24

2.4

3.8

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.35

0.24

1.2

1.6

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.21

0.0

1.0

—

(40768793) Breast Pathology biopsy report

0.00

0.21

0.0

1.1

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.21

0.0

2.0

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.21

0.0

1.0

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.21

0.0

2.4

—

(3026285) Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.1

—

1.34

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.21

0.0

1.0

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.1

—

(1616796) Gas panel - Central venous blood

0.00

0.21

0.0

4.1

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.4

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.21

0.0

1.0

—

(3045414) Leukocytes [Presence] in Urine

1.31

0.21

2.7

1.9

—

0.00

estimate

—

(3011288) Drugs identified in Urine by Screen method Nominal

0.00

0.21

0.0

2.4

—

(4094501) Cardiovascular stress test using bicycle ergometer

0.00

0.21

0.0

1.1

—

(3003327) Ova and parasites identified in Stool by Light microscopy

0.00

0.21

0.0

1.5

—

(21494755) Public health laboratory ask at order entry panel

1.20

0.20

1.3

1.4

—

(3018095) Leukocytes [#/volume] in Urine

158

1.22

0.20

3.3

3.2

35.80

47.34

e6/l

0.13

113

(3002256) Pathology report gross observation

1.22

0.19

1.6

1.2

—

(42870588) Differential panel, method unspecified - Blood

149

1.21

0.19

8.6

5.2

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.17

0.18

1.7

2.2

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.23

0.18

1.3

1.7

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

165

0.87

0.10

2.8

4.3

109.78

43.05

ng/l

—

106

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.10

0.09

1.2

2.2

—

(3044889) 12 lead EKG panel

296

1.12

0.09

3.8

4.0

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

163

0.89

0.08

2.9

3.6

—

0.00

estimate

—

(3019550) Sodium [Moles/volume] in Serum or Plasma

436

1.27

0.08

25.0

15.8

139.29

139.73

mmol/l

0.62

428

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

130

1.11

0.05

5.0

4.3

34.82

22.29

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

173

1.06

0.01

11.6

6.3

1.20

1.22

mmol/l

0.55

163

(3021601) Nitrite [Presence] in Urine by Test strip

216

0.95

0.00

3.1

3.5

—

0.00

estimate

—

(3013512) EKG study

133

0.97

0.00

3.2

3.6

—

(3009261) Glucose [Presence] in Urine by Test strip

221

0.99

0.00

3.1

3.6

—

0.00

estimate

—

(3015736) pH of Urine

167

1.03

0.00

2.8

3.1

5.88

6.11

—

104

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

145

1.05

0.00

3.6

3.0

—

(40760892) CBC W Ordered Manual Differential panel - Blood

106

1.05

0.00

3.0

4.3

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

-0.00

0.0

1.6

—

62.50

—

(3005715) Vancomycin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

3.7

—

10.58

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

-0.00

0.0

1.3

—

(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

12.70

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

13.3

—

924.83

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.2

—

(40768800) Prostate Pathology biopsy report

0.00

-0.00

0.0

1.1

—

(3013290) Carbon dioxide [Partial pressure] in Blood

0.00

-0.00

0.0

3.5

—

4.81

—

(3045716) Anion gap in Serum or Plasma by calculation

0.00

-0.00

0.0

2.3

—

11.00

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.3

—

(3045156) Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

6.2

—

4.50

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.4

—

104.20

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.4

—

1.17

—

(3022803) Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

6.2

—

9.78

—

(3025547) Thyroglobulin Ab [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.4

—

13.25

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

-0.00

0.0

2.6

—

(3019539) Treponema pallidum Ab [Titer] in Serum by Hemagglutination

0.00

-0.00

0.0

1.6

—

(3032700) Glomerular basement membrane Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

(3029634) Reagin Ab [Titer] in Serum by VDRL

0.00

-0.00

0.0

1.8

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

15.3

—

1456.33

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

-0.00

0.0

1.5

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

0.00

-0.00

0.0

1.3

—

33.17

—

(3042631) Mycobacterium sp identified in Specimen

0.00

-0.00

0.0

6.4

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

5.6

—

21.71

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

-0.00

0.0

2.0

—

(3010421) pH of Blood

0.00

-0.00

0.0

6.1

—

7.42

—

(3012110) Lysozyme [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.5

—

10.59

—

(3018301) Testosterone Free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.1

—

197.14

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

0.00

-0.00

0.0

1.2

—

(3027315) Oxygen [Partial pressure] in Blood

0.00

-0.00

0.0

3.5

—

8.24

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.4

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.4

—

3.80

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

0.99

-0.00

1.8

1.9

—

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_YAWNS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have AB1_YAWNS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: AB1_YAWNS – Yaws

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Yaws

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints